FDA Cybersecurity Premarket (Section 524B)

Congress added section 524B to the Federal Food, Drug, and Cosmetic Act on December 29, 2022 through the Consolidated Appropriations Act. The provision elevates cybersecurity expectations from guidance to statutory obligation for any premarket submission that includes a qualifying cyber device. FDA began enforcing refusal-to-accept screening for missing cybersecurity content on October 1, 2023.

The statute requires manufacturers to implement a Secure Product Development Framework, maintain and submit a Software Bill of Materials, and establish processes to monitor, disclose, and timely patch vulnerabilities. Sponsors must provide reasonable assurance that the device and related systems are cybersecure across the product lifecycle.

FDA’s 2023 cybersecurity guidance operationalizes section 524B within the device design and risk management paradigm. It aligns security activities with design controls, verification, validation, and labeling, while emphasizing secure configuration, authentication, cryptography, logging, update mechanisms, and resilience against known vulnerabilities and foreseeable misuse.

A device falls under section 524B when it incorporates software validated, installed, or authorized by the sponsor, can connect to the internet or another device, and could be vulnerable to cybersecurity threats. The definition is technology-agnostic and captures system-of-systems comprising device firmware, companion apps, and cloud services that enable device functions.

Software as a Medical Device, accessories that add connectivity, and embedded software in traditional devices can all be in scope if connectivity and vulnerability criteria are met. Conversely, devices without software or external connectivity, or where connectivity is permanently disabled and cannot be re-enabled by users or service personnel, typically fall outside 524B.

The requirement applies across premarket pathways, including 510(k), De Novo, and PMA. Substantially equivalent claims do not waive cybersecurity obligations. Sponsors should consider the total product architecture and threat exposure in home, clinic, and enterprise contexts to avoid under-scoping the security boundary.

• Examples in scope: connected infusion pumps, implantable devices with telemetry, remote patient monitoring platforms, networked imaging modalities, and SaMD with cloud dependencies.
• Examples typically out of scope: purely mechanical devices with no software, no connectivity, and no plausible path for cyber exploitation.

Early architectural choices strongly influence later security posture. For complex software-centric products, plan cybersecurity and documentation concurrently with clinical, usability, and regulatory strategies described in Software as a Medical Device (SaMD) readiness.

In practice, section 524B requires sponsors to embed cybersecurity in design controls, not to bolt it on at release. A Secure Product Development Framework structures activities from requirements to maintenance: threat modeling, secure coding, static and dynamic analysis, hardening, security testing, and change control.

Premarket submissions must present a coherent security case that traces identified threats to implemented controls and objective evidence. FDA expects traceability from hazard and threat scenarios through risk controls, verification, and labeling, with clear residual risk rationale and plans for handling newly discovered vulnerabilities after clearance or approval.

Pre-submission interactions help align scope, evidence depth, and test methods. For software life-cycle alignment, organizations commonly map SPDF activities to IEC 62304 processes; see the readiness perspective in IEC 62304 medical device software readiness. Cybersecurity also fits within FDA’s quality management expectations described in the FDA QMSR, which harmonizes with ISO 13485.

Sponsors should ensure supplier management processes address third-party and open-source software risks, including versioning, known vulnerabilities, provenance, and update strategies. These topics must connect to the SBOM and to the field update mechanism described in the submission and device labeling.

FDA expects cybersecurity content to be organized, consistent, and evidence-backed. The submission should explain the product’s security architecture, the threat model, mitigations, and how effectiveness was verified. The narrative must be traceable to an SBOM that is complete, accurate, and kept current, including third‑party and open‑source components and their versions.

Security testing should be risk‑based and repeatable, commonly including requirements‑based testing, static analysis, software composition analysis, fuzzing, and authenticated penetration testing scoped to the system boundary. The results must be interpretable, with severity ratings, exploitability rationale, and remediation status.

Labeling must convey secure configuration, authentication and authorization practices, logging, update procedures, and operational environments. Security‑relevant instructions belong in the Instructions for Use (IFU) and administrator materials. Postmarket monitoring and coordinated vulnerability disclosure plans should explain intake, triage, remediation, communication, and patch delivery timelines.

An effective SPDF institutionalizes security within product engineering. It assigns roles, codifies secure requirements, and makes security reviews a standing part of design decisions. It measures process performance and uses feedback from testing and field incidents to drive continuous improvement.

FDA does not mandate a specific standard, but alignment to recognized practices strengthens submissions. Many manufacturers map SPDF controls to ISO 13485 design controls, IEC 62304 software lifecycle activities, and NIST secure software development principles. This triangulation demonstrates process maturity, repeatability, and coverage of both preventive and detective controls.

Operationally, SPDFs should ensure that vulnerabilities discovered late in development or postmarket route through formal change control, with risk reassessment, regression testing, and deployment orchestration. Release notes and customer communications should plainly state security impact, exploitability, and required actions.

• Define security gates at requirements, architecture, code complete, verification complete, and release readiness.
• Require component provenance checks and vulnerability baselining before integration.
• Automate code, dependency, and container scanning in CI pipelines with documented triage.
• Rehearse update and rollback procedures, including cryptographic signing and recovery.
• Establish a Product Security Incident Response Team with clear SLAs for intake and fixes.

Risk‑informed governance should also cover long‑lived assets and fielded configurations. Include cadence for security reviews of deployed software and connected services, as described in Periodic review of computerized systems, and embed secure change practices that reinforce Data integrity by design.

Section 524B requires credible plans to monitor, detect, and remediate vulnerabilities once the device is marketed. Manufacturers should define telemetry, log review, threat intelligence intake, and vulnerability scanning practices proportionate to their risk profile. The plan must articulate how issues are triaged and how patches or compensating controls are deployed.

Coordinated Vulnerability Disclosure frameworks help balance patient safety with timely information sharing. Manufacturers commonly publish a CVD policy, establish intake channels, and commit to response timeframes. When a fix is not immediately feasible, the risk rationale and interim mitigations should be transparent, testable, and communicated to operators and administrators.

Because software supply chains evolve, postmarket practices should explicitly track component versions against known vulnerabilities and plan end‑of‑support transitions. Monitoring should tie into customer notifications, service bulletins, and distribution of signed updates. Evidence of these activities supports inspections and complaint trend analysis within broader post‑market surveillance programs.

Under-scoping is the most frequent error. Sponsors sometimes present device-only controls while ignoring the companion mobile app, cloud service, or clinical network interfaces that materially affect security posture. FDA evaluates the system boundary that enables the device’s intended use.

Another recurring issue is treating the SBOM as a static inventory rather than a living artifact tied to build pipelines and release governance. Without version fidelity and vulnerability monitoring, the SBOM provides little assurance and can undermine claims about patch timeliness.

• Submitting an SBOM without versions, transitive dependencies, or provenance.
• Threat models that list hazards but do not link mitigations or verification evidence.
• Security testing focused on functionality, with minimal fuzzing or authenticated penetration testing.
• Labeling that omits secure configuration, logging, or update procedures for administrators.
• Patch plans that lack timelines, distribution mechanisms, or rollback procedures.
• Supplier controls that ignore licensing, vulnerability debt, or end‑of‑support for third‑party components, despite an approved supplier list.

The 524B mandate complements, rather than duplicates, international frameworks. EU MDR and IVDR require manufacturers to address cybersecurity as part of safety and performance, often assessed by notified bodies against harmonized standards and guidance. Documentation needs are similar, but formats and terminology can differ by regulator and conformity assessment route.

FDA’s expectations align well with NIST secure development practices and ISO 13485 design controls. Organizations that already operate an information security management system can leverage controls and audit evidence for device cybersecurity, provided they show product‑specific risk analysis and testing.

AI‑enabled devices introduce additional attack surfaces in data pipelines and model deployment. While 524B is technology‑agnostic, sponsors should integrate adversarial robustness and model update controls with their broader SPDF, and consider how evolving EU AI requirements will intersect with device safety and performance claims.

For usability‑driven mitigations, ensure that human factors instructions and administrative controls are reflected in labeling and validated workflows. These linkages help demonstrate that operators can implement the security posture that the risk assessment assumes in clinical and home settings.

Relevant cross-references include ISO/IEC 27001 controls for asset management, access control, vulnerability management, and incident response, EU guidance on device cybersecurity in MDR technical documentation, and FDA’s quality rule harmonization. A harmonized approach reduces duplication and clarifies assurance arguments for global submissions.

For strategic alignment and horizon scanning on regulatory AI and cybersecurity convergence, see the EU AI Act for medical devices and leverage your enterprise information security certifications such as ISO/IEC 27001:2022.

FDA applies section 524B across major premarket pathways. For 510(k), cybersecurity does not hinge on substantial equivalence; even if a predicate lacked connectivity or security controls, the new device must address contemporary threats. For De Novo and PMA, the depth of evidence typically grows with complexity and risk.

Sponsors should plan cybersecurity content in lockstep with clinical and performance evidence. Begin early architecture reviews, confirm test strategies, and validate update and rollback mechanisms on representative hardware and networks. If tradeoffs affect user workflows or clinical performance, close the loop with labeling and usability validation.

Use early interactions to clarify evidence expectations and test methods. Provide draft SBOM formats, threat models, and test protocols for feedback. Maintain a clean traceability thread that ties threats to mitigations, verification, and labeling, and point to public vulnerability disclosure resources that will be active post-clearance.

1. Survey predicates and recent clearances in the FDA 510(k) database to benchmark cybersecurity disclosures.
2. Plan equivalence arguments with caution; do not rely on a predicate device to justify gaps in contemporary security.
3. Pre‑align in a Q‑Sub on scope, test coverage, and SBOM expectations, then lock protocols before verification starts.
4. Reserve submission narrative space to summarize residual risk and postmarket commitments, including patch timelines and customer communication.

Sponsors of software-intensive products should also align with SaMD principles and life-cycle discipline. Doing so reduces rework when the same product is prepared for multiple markets with differing documentation conventions and assurance emphases.

Meeting 524B is as much a documentation and traceability challenge as it is a technical one. V5 Ultimate centralizes SPDF policies, secure development SOPs, training records, and stage‑gate evidence, linking them directly to design outputs, risk controls, verification results, and release notes. The result is a cohesive security case that is easier to audit and defend.

SBOMs can be governed alongside supplier qualification and change control, while testing artifacts from static analysis, composition analysis, fuzzing, and penetration testing are versioned, reviewed, and dispositioned with clear ownership and due dates. Security labeling and administrator guidance are managed as controlled documents with automated periodic review and expiry alerts.

Postmarket monitoring, PSIRT workflows, and customer notifications are orchestrated in one place, ensuring that vulnerability intake, triage, remediation, and communication remain consistent and auditable. Dashboards surface patch SLAs, open findings by severity, and field deployment status to support management review and inspection readiness.